Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +0.20%19 EBITDA Margin % is 28.38% as of Dec. 2025, which is 21% above its 10-year median of 23.38. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Pet Pharm Biotech Co ranks better than 80.81% on this metric.
Pet Pharm Biotech Co (ROCO:7762) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pet Pharm Biotech Co EBITDA Margin % Related Terms
Pet Pharm Biotech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a EBITDA Margin % of 28.38% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pet Pharm Biotech Co and its competitors. This is 21% above median its historical median of 23.38. Over the past decade, Pet Pharm Biotech Co's EBITDA Margin % has ranged from 14.11 to 26.87. According to the industry distribution chart, Pet Pharm Biotech Co ranks #184 out of 959 companies in the Drug Manufacturers industry, placing it in the top 19.2%.
Is Pet Pharm Biotech Co's EBITDA Margin % too high?
Pet Pharm Biotech Co's current EBITDA Margin % of 28.38% is 21% above median its 10-year median of 23.38. Over the past 10 years, this metric has ranged from a low of 14.11 to a high of 26.87. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Pet Pharm Biotech Co's value of 28.38% is 126.3% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #184 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #184 out of 959 companies for EBITDA Margin %. This places Pet Pharm Biotech Co in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. Pet Pharm Biotech Co's value of 28.38% is 126.3% above this benchmark. Historically, Pet Pharm Biotech Co's own EBITDA Margin % has ranged from 14.11 to 26.87 over the past decade. While the company's 10-year median is 23.38 vs. the industry median of 12.54, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current EBITDA Margin % of 28.38% is 126.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current EBITDA Margin % is 28.38%, which is 21% above median its own 10-year median of 23.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current EBITDA Margin % of 28.38%. The current EBITDA Margin % is 28.38%, which is 21% above median its 10-year median of 23.38 and 126.3% above the Drug Manufacturers industry median of 12.54. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current EBITDA Margin % is 28.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score
Get the complete analysis for ROCO:7762
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
